Tagraxofusp
Elzonris (tagraxofusp) is a protein pharmaceutical. Tagraxofusp was first approved as Elzonris on 2018-12-21. It is used to treat malignant histiocytic disorders in the USA. It has been approved in Europe to treat lymphoma.
| Trade Name | Elzonris |
|---|---|
| Common Name | Tagraxofusp |
| Indication | lymphoma, malignant histiocytic disorders |
| Drug Class | Fusion proteins |
